Eli Lilly Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 5/6
Eli Lilly hat ein Gesamteigenkapital von $33.9B und eine Gesamtverschuldung von $54.9B, wodurch sich der Verschuldungsgrad auf 162.1% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $142.3B bzw. $108.4B. Eli Lilly Das EBIT des Unternehmens beträgt $39.6B, so dass der Zinsdeckungsgrad 215.3 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $9.0B.
Wichtige Informationen
162.07%
Verhältnis von Schulden zu Eigenkapital
US$54.91b
Verschuldung
| Zinsdeckungsgrad | 215.3x |
| Bargeld | US$8.95b |
| Eigenkapital | US$33.88b |
| Gesamtverbindlichkeiten | US$108.40b |
| Gesamtvermögen | US$142.28b |
Jüngste Berichte zur Finanzlage
Keine Aktualisierungen
Recent updates
Narrative-Update • Sep 19
LLY: GLP-1 And Obesity Franchise Strength Will Drive Future Upside
Analysts have nudged their average price target for Eli Lilly higher as updated models reflect stronger GLP-1 prescription trends, increased demand in the obesity franchise, and recent price target increases that now cluster around the $1,300 to $1,600 range. Analyst Commentary Recent research updates on Eli Lilly show a wide range of views, but most price targets sit well above the US$900 level, with several clustered between US$1,300 and US$1,600.Seeking Alpha • Sep 05
Eli Lilly Stock Is Not Done Growing Yet, But It's Due For Compression (Rating Downgrade)
Summary Eli Lilly remains attractive versus overextended semiconductor stocks, offering a compelling short-term entry point within healthcare's more favorable valuation landscape. LLY's forward P/E of 31.5 is high, but its PEG ratio of 1.49 suggests growth justifies the premium relative to sector peers. Healthcare, led by LLY, can benefit from rotation out of crowded tech but remains correlated to broader equity sentiment and vulnerable in a market-wide selloff. LLY's Q2 revenue surged 48% on Mounjaro and Zepbound, positioning it to potentially outperform semiconductors, though not immune to systemic risk. Read the full article on Seeking Alpha
Narrative-Update • Sep 05
LLY: Incretin Obesity Franchise And Pipeline Will Support Premium Positioning Beyond 2030
The analyst fair value estimate for Eli Lilly has been raised from $1,500 to $1,600 as analysts point to strong Q2 incretin volume, obesity drug demand, and upgraded multi-year guidance as key supports for higher long-term assumptions. Analyst Commentary Recent Street research on Eli Lilly points to a broadly constructive tone, with many bullish analysts lifting price targets after Q2 results and updated guidance.
Neues Narrative • Sep 03
Eli Lilly — Leader of the GLP-1 Revolution, but Priced for Success
Eli Lilly is the leader of the obesity/diabetes revolution (GLP-1 drugs like tirzepatide), addressing one of the largest addressable markets in medical history. It's my highest-quality healthcare growth bet.
Narrative-Update • Aug 22
LLY: Obesity Franchise Concentration And Pricing Pressure Will Constrain Future Upside
Analysts have lifted the Eli Lilly fair value estimate from $899.73 to $982.09. Higher price targets reflect confidence that strong incretin demand, obesity franchise momentum and updated long-term guidance support a slightly higher assumed future P/E and profit margin, even with a modestly higher discount rate and tempered revenue growth inputs.Analyseartikel • Aug 08
Eli Lilly and Company Just Beat Revenue By 11%: Here's What Analysts Think Will Happen Next
Eli Lilly and Company ( NYSE:LLY ) just released its quarterly report and things are looking bullish. It was a positive...Narrative-Update • Aug 08
LLY: GLP-1 Leadership And Retatrutide Progress Will Drive Balanced Outlook
Analysts have increased their fair value estimate for Eli Lilly stock from $1,270.37 to $1,297.31, reflecting higher Street price targets supported by strong Q2 incretin demand, GLP-1 franchise momentum, and updated long-term modeling around obesity and diabetes therapies. Analyst Commentary Recent Street research on Eli Lilly shows a clear focus on the company’s incretin and GLP-1 portfolio, with multiple firms adjusting price targets following Q2 results, obesity and diabetes trial updates, and refreshed long term models.Narrative-Update • Jul 25
LLY: GLP-1 Leadership And Retatrutide Data Will Shape Balanced Outlook
Eli Lilly's updated fair value estimate of $1,270.37, up from $1,243.43, reflects analysts' higher price targets that lean on expectations for stronger obesity and diabetes franchise contributions, incremental support from retatrutide data, and Q2 previews that factor in relatively higher revenue growth assumptions alongside slightly adjusted long term profit margins and future P/E multiples. Analyst Commentary Recent research on Eli Lilly points to a generally constructive stance from Wall Street, with multiple firms lifting price targets as they reassess the company's obesity and diabetes portfolio, retatrutide data, and Q2 earnings setup.Narrative-Update • Jul 10
LLY: GLP-1 Franchise And Retatrutide Data Will Support Balanced Future Outlook
Analysts have nudged their price targets on Eli Lilly higher, with fair value estimates moving from about $1,218.72 to roughly $1,243.43 as they point to resilient GLP-1 obesity and diabetes franchises, along with supportive recent data and previews around Zepbound, Mounjaro, Foundayo and retatrutide. Analyst Commentary Recent research updates on Eli Lilly show a cluster of higher price targets around the GLP-1 obesity and diabetes portfolio, with Zepbound, Mounjaro, Foundayo and retatrutide at the center of the discussion.Narrative-Update • Jun 24
LLY: Retatrutide Efficacy And GLP-1 Demand Will Support Balanced Outlook
Analysts have nudged up Eli Lilly's fair value estimate by about $4 to $1,218.72, reflecting modestly higher modeled revenue growth and a slightly richer future P/E multiple, supported by recent price target increases tied to retatrutide data and broader GLP-1 expectations. Analyst Commentary Recent commentary on Eli Lilly centers on how retatrutide data and GLP-1 demand expectations filter into valuation, growth assumptions, and execution risk.Narrative-Update • Jun 09
LLY: GLP-1 Leadership And Retatrutide Data Will Support Balanced Long-Term Outlook
Analysts have inched up their price targets on Eli Lilly, with several moving into the $1,250 to $1,350 range. They cite full Phase 3 retatrutide data that showed strong obesity and Type 2 diabetes outcomes, with what they view as manageable safety trade offs and a GLP-1 profile they say will be hard for rivals to match.Narrative-Update • May 26
LLY: GLP-1 Obesity Franchise Leadership Will Drive Long-Term Profitability
Analysts have nudged their price targets on Eli Lilly higher, with our fair value estimate moving by about $2 to $1,211 per share as they factor in expectations for stronger long-term profitability and GLP-1 leadership following positive retatrutide Phase 3 data, partly offset by more tempered revenue growth assumptions and a lower future P/E multiple. Analyst Commentary Recent research on Eli Lilly clusters around the same theme, retatrutide Phase 3 data supporting a premium valuation for the GLP-1 franchise, but with growing debate over how much future growth is already reflected in the stock.Narrative-Update • May 07
LLY: Obesity Pricing Pressure And Safety Headlines Will Shape Future Franchise Economics
Analysts have raised Eli Lilly's implied fair value from $883.99 to $899.73 after several firms increased their price targets by $1 to $50, citing confidence in the obesity and diabetes pipeline, Foundayo's regulatory progress, and clarifications around recent safety concerns. Analyst Commentary Recent research on Eli Lilly reflects a mix of enthusiasm around obesity and diabetes assets and a clearer, more cautious minority that is focused on how much optimism is already reflected in the stock.Narrative-Update • Apr 20
LLY: Obesity And Diabetes Platform Will Support Premium Positioning Beyond 2030
Analysts have slightly raised their average price targets on Eli Lilly in recent weeks, citing supportive trial updates in obesity and diabetes, favorable comparisons to competing GLP-1 therapies, and regulatory progress that they say supports high but unchanged fair value estimates of around $1,500. Analyst Commentary Recent Street research around Eli Lilly has been active, with a cluster of price target moves, rating changes, and product specific notes that give you a clearer sense of how professionals are framing the risk and reward.Narrative-Update • Apr 06
LLY: Oral GLP-1 Launch And Capacity Expansion Will Drive Future Obesity Upside
Analysts have nudged Eli Lilly's price target slightly higher by $1, reflecting updated views on obesity and diabetes franchises following recent Foundayo approval commentary and comparative GLP-1 data. Analyst Commentary Recent research on Eli Lilly clusters around obesity and diabetes, pricing dynamics in GLP-1 therapies, and the implications of new product approvals and trial readouts for long term growth and valuation.Neues Narrative • Mar 25
Eli Lilly: A Pipeline-Driven Growth Story Trading 30% Below What the Business Is Actually Worth
Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet. WHERE THE STOCK SITS TODAY The current price is around $907 (25/03/2026).Narrative-Update • Mar 23
LLY: Obesity And Diabetes Franchise Strength Will Support Premium Positioning
Analysts have raised their price target for Eli Lilly to $1,500, citing updated models that reflect slightly stronger assumed revenue growth, a marginally higher profit margin profile, and continued confidence in the obesity and diabetes franchises following recent trial data and supportive sell side research. Analyst Commentary Recent research highlights a split view on Eli Lilly, with some bullish analysts leaning into the obesity and diabetes opportunity set, while at least one more cautious voice questions how much growth is already reflected in the share price.Narrative-Update • Mar 09
LLY: Obesity Drug Leadership And Pipeline Catalysts Will Sustain Premium Positioning
The updated analyst price target for Eli Lilly has increased to $1,490.52 from $1,429.89. Analysts highlight the obesity and GLP-1 franchise, premium valuations tied to weight loss leadership, and potential upside from pipeline and acquisition catalysts as key factors supporting this change.Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: LLYDie kurzfristigen Aktiva des Unternehmens ($64.7B) übersteigen seine kurzfristigen Passiva ($47.7B).
Langfristige Verbindlichkeiten: LLYDie kurzfristigen Vermögenswerte des Unternehmens ($64.7B) übersteigen seine langfristigen Verbindlichkeiten ($60.7B).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: LLYDie Nettoverschuldung im Verhältnis zum Eigenkapital (135.7%) wird als hoch angesehen.
Schulden abbauen: LLY Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 249.2% auf 162.1% zurückgegangen.
Schuldendeckung: LLYDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (51.1%).
Zinsdeckung: LLYDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (215.3x Coverage) gut gedeckt.
Bilanz
Entdecken Sie finanziell stabile Unternehmen
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/21 03:58 |
| Aktienkurs zum Tagesende | 2026/09/21 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Eli Lilly and Company wird von 54 Analysten beobachtet. 28 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| "Emily Field | Barclays |